![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EUROSCREEN FILES A CCR5 PATENT COMPLAINT AGAINST ONO PHARMACEUTICAL CO., LTD
EUROSCREEN FILES A CCR5 PATENT COMPLAINT AGAINST ONO PHARMACEUTICAL CO., LTD
August 11, 2006
Euroscreen s.a. announced that it filed a complaint in the Osaka District Court (case number H18 (wa) 7760) alleging that Ono Pharmaceuticals Co., Ltd. infringed a basic CCR5 patent (JP Patent No. 3288384) in the discovery of Ono's CCR5 drug candidates. Ono has partnered these candidates with GSK. PR Web (http://www.prweb.com/releases/2006/8/prweb422382.htm)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct